INSIGNIA
Are You Eligible?This trial is testing a new investigational medication in adults with high blood pressure in the lungs (pulmonary hypertension or PH) related to chronic obstructive pulmonary disease (COPD)
Research Objectives
Status
Recruitment
Total participants required
Study location
Study type
Patient group
About this clinical trial
Pulmonary Hypertension is a serious condition characterised by high blood pressure in the blood vessels of the lungs. Unlike regular blood pressure measured in the arm, PH refers to the pressure inside the vessels within the lungs, which can only be confirmed through an invasive procedure. This elevated lung pressure causes patients to feel short of breath and, if left untreated, can ultimately lead to right heart failure and death.
This trial is testing a new investigational medicine in adults with high blood pressure in the lungs (pulmonary hypertension or PH) related to chronic obstructive pulmonary disease (COPD).
The treatment is a once daily inhaler, which is used in conjunction with your other prescribed medications. The trial lasts approximately 6 months with 10 study visits.
Eligibility
- Patients with Group 3 Pulmonary hypertension– COPD
- Aged 40-85 years
- BMI 18.5-40
Lead investigator
- Dr John Feenstra
Clinical trial coordinator
- Bronwen Field
Contact Us
If you would like more information about this clinical trial, please complete the contact form below.